CD38 as an Immunomodulator in Cancer

References

• Reinherz EL , KungPC, GoldsteinG, LeveyRH, SchlossmanSF. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc. Natl. Acad. Sci. USA77(3), 1588–1592 (1980).
   PubMed Web of Science ®Google Scholar
• Terhorst C , van AgthovenA, LeclairK, SnowP, ReinherzE, SchlossmanS. Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10. Cell23(3), 771–780 (1981).
   PubMed Web of Science ®Google Scholar
• Malavasi F , FunaroA, AlessioMet al. CD38: a multi-lineage cell activation molecule with a split personality. Int. J. Clin. Lab. Res.22(2), 73–80 (1992).
   PubMedGoogle Scholar
• Jackson DG , BellJI. Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J. Immunol.144(7), 2811–2815 (1990).
   PubMed Web of Science ®Google Scholar
• Malavasi F , FunaroA, RoggeroS, HorensteinA, CalossoL, MehtaK. Human CD38: a glycoprotein in search of a function. Immunol. Today15(3), 95–97 (1994).
   PubMedGoogle Scholar
• Funaro A , HorensteinAL, CalossoLet al. Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids. Int. Immunol.8(11), 1643–1650 (1996).
   PubMed Web of Science ®Google Scholar
• Vences-Catalan F , Santos-ArgumedoL. CD38 through the life of a murine B lymphocyte. IUBMB Life63(10), 840–846 (2011).
   PubMed Web of Science ®Google Scholar
• Lund F , SolvasonN, GrimaldiJC, ParkhouseRM, HowardM. Murine CD38: an immunoregulatory ectoenzyme. Immunol. Today16(10), 469–473 (1995).
   PubMedGoogle Scholar
• Mehta K , ShahidU, MalavasiF. Human CD38, a cell-surface protein with multiple functions. FASEB J.10(12), 1408–1417 (1996).
   PubMed Web of Science ®Google Scholar
• Guse AH , DaSilva CP, BergIet al. Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose. Nature398(6722), 70–73 (1999).
   PubMed Web of Science ®Google Scholar
• Lund FE , Muller-SteffnerHM, YuN, StoutCD, SchuberF, HowardMC. CD38 signaling in B lymphocytes is controlled by its ectodomain but occurs independently of enzymatically generated ADP-ribose or cyclic ADP-ribose. J. Immunol.162(5), 2693–2702 (1999).
   PubMed Web of Science ®Google Scholar
• Nishina H , InagedaK, TakahashiK, HoshinoS, IkedaK, KatadaT. Cell surface antigen CD38 identified as ecto-enzyme of NAD glycohydrolase has hyaluronate-binding activity. Biochem. Biophys. Res. Commun.203(2), 1318–1323 (1994).
   PubMed Web of Science ®Google Scholar
• Deaglio S , MalloneR, BajGet al. CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes. Chem. Immunol.75(1015-0145), 99–120 (2000).
   PubMedGoogle Scholar
• Nata K , TakamuraT, KarasawaTet al. Human gene encoding CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase): organization, nucleotide sequence and alternative splicing. Gene186(2), 285–292 (1997).
   PubMed Web of Science ®Google Scholar
• Liu Q , KriksunovIA, GraeffR, MunshiC, LeeHC, HaoQ. Crystal structure of human CD38 extracellular domain. Structure13(9), 1331–1339 (2005).
   PubMed Web of Science ®Google Scholar
• Malavasi F , DeaglioS, FunaroAet al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol. Rev.88(3), 841–886 (2008).
   PubMed Web of Science ®Google Scholar
• Morra M , ZubiaurM, TerhorstC, SanchoJ, MalavasiF. CD38 is functionally dependent on the TCR/CD3 complex in human T cells. FASEB J.12(7), 581–592 (1998).
   PubMed Web of Science ®Google Scholar
• Janossy G , TidmanN, PapageorgiouES, KungPC, GoldsteinG. Distribution of T lymphocyte subsets in the human bone marrow and thymus: an analysis with monoclonal antibodies. J. Immunol.126(4), 1608–1613 (1981).
   PubMed Web of Science ®Google Scholar
• Bataille R , JegoG, RobillardNet al. The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy. Haematologica91(9), 1234–1240 (2006).
   PubMed Web of Science ®Google Scholar
• Cesano A , VisonneauS, DeaglioS, MalavasiF, SantoliD. Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells. J. Immunol.160(3), 1106–1115 (1998).
   PubMed Web of Science ®Google Scholar
• Dixit S , SinghA, Mamatha GS, Desai RS, JajuP. Apert’s syndrome: report of a new case and its management. Int. J. Clin. Pediatr. Dent.1(1), 48–53 (2008).
   PubMedGoogle Scholar
• Laubach JP , TaiYT, RichardsonPG, AndersonKC. Daratumumab granted breakthrough drug status. Expert Opin. Investig. Drugs23(4), 445–452 (2014).
   PubMed Web of Science ®Google Scholar
• Lin P , OwensR, TricotG, WilsonCS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am. J. Clin. Pathol.121(4), 482–488 (2004).
   PubMed Web of Science ®Google Scholar
• van De Donk NW , JanmaatML, MutisTet al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol. Rev.270(1), 95–112 (2016).
   PubMed Web of Science ®Google Scholar
• Boslett J , HemannC, ChristofiFL, ZweierJL. Characterization of CD38 in the major cell types of the heart: endothelial cells highly express CD38 with activation by hypoxia/reoxygenation depleting NAD(P)H. Am. J. Physiol. Cell Physiol.314(3), C297–C309 (2017).
   PubMed Web of Science ®Google Scholar
• Guan XH , HongX, ZhaoNet al. CD38 promotes angiotensin II-induced cardiac hypertrophy. J. Cell. Mol. Med.21(8), 1492–1502 (2017).
   PubMed Web of Science ®Google Scholar
• Schiavoni I , ScagnolariC, HorensteinALet al. CD38 modulates respiratory syncytial virus-driven proinflammatory processes in human monocyte-derived dendritic cells. Immunology154(1), 122–131 (2017).
   PubMed Web of Science ®Google Scholar
• Lins L , FariasE, Brites-AlvesC, TorresA, NettoEM, BritesC. Increased expression of CD38 and HLADR in HIV-infected patients with oral lesion. J. Med. Virol.89(10), 1782–1787 (2017).
   PubMed Web of Science ®Google Scholar
• Wursch D , OrmsbyCE, Romero-RodriguezDPet al. CD38 expression in a subset of memory T cells is independent of cell cycling as a correlate of HIV disease progression. Dis. Markers2016, 9510756 (2016).
   PubMed Web of Science ®Google Scholar
• Deshpande DA , GuedesAG, LundFE, SubramanianS, WalsethTF, KannanMS. CD38 in the pathogenesis of allergic airway disease: potential therapeutic targets. Pharmacol. Ther.172, 116–126 (2017).
   PubMed Web of Science ®Google Scholar
• Henriques A , SilvaI, InesLet al. CD38, CD81 and BAFFR combined expression by transitional B cells distinguishes active from inactive systemic lupus erythematosus. Clin. Exp. Med.16(2), 227–232 (2016).
   PubMed Web of Science ®Google Scholar
• Mallone R , OrtolanE, PinachSet al. Anti-CD38 autoantibodies: characterisation in new-onset Type I diabetes and latent autoimmune diabetes of the adult (LADA) and comparison with other islet autoantibodies. Diabetologia45(12), 1667–1677 (2002).
   PubMed Web of Science ®Google Scholar
• Mallone R , PerinPC. Anti-CD38 autoantibodies in type? diabetes. Diabetes Metab. Res. Rev.22(4), 284–294 (2006).
   PubMed Web of Science ®Google Scholar
• Kim BJ , ChoiYM, RahSYet al. Seminal CD38 is a pivotal regulator for fetomaternal tolerance. Proc. Natl. Acad. Sci. USA112(5), 1559–1564 (2015).
   PubMed Web of Science ®Google Scholar
• Higashida H , MunesueT. [CD38 and autism spectrum disorders]. No To Hattatsu45(6), 431–435 (2013).
   PubMedGoogle Scholar
• Boini KM , XiaM, XiongJ, LiC, PayneLP, LiPL. Implication of CD38 gene in podocyte epithelial-to-mesenchymal transition and glomerular sclerosis. J. Cell. Mol. Med.16(8), 1674–1685 (2012).
   PubMed Web of Science ®Google Scholar
• Joosse ME , MenckebergCL, DeRuiter LFet al. Frequencies of circulating regulatory TIGIT+CD38+ effector T cells correlate with the course of inflammatory bowel disease. Mucosal Immunol.12(1), 154–163 (2019).
   PubMed Web of Science ®Google Scholar
• Wang H , LiS, ZhangG, WuH, ChangX. Potential therapeutic effects of cyanidin-3-O-glucoside on rheumatoid arthritis by relieving inhibition of CD38+ NK cells on Treg cell differentiation. Arthritis Res. Ther.21(1), 220–220 (2019).
   PubMed Web of Science ®Google Scholar
• Deaglio S , MehtaK, MalavasiF. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk. Res.25(1), 1–12 (2001).
   PubMed Web of Science ®Google Scholar
• Quarona V , ZaccarelloG, ChillemiAet al. CD38 and CD157: a long journey from activation markers to multifunctional molecules. Cytometry B Clin. Cytom.84(4), 207–217 (2013).
   PubMedGoogle Scholar
• Zeijlemaker W , GrobT, MeijerRet al. CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia33(5), 1102–1112 (2019).
   PubMed Web of Science ®Google Scholar
• Malavasi F , DeaglioS, DamleR, CutronaG, FerrariniM, ChiorazziN. CD38 and chronic lymphocytic leukemia: a decade later. Blood118(13), 3470–3478 (2011).
   PubMed Web of Science ®Google Scholar
• Damle RN , WasilT, FaisFet al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood94(6), 1840–1847 (1999).
   PubMed Web of Science ®Google Scholar
• Liu X , GroganTR, HieronymusHet al. Low CD38 identifies progenitor-like inflammation-associated luminal cells that can initiate human prostate cancer and predict poor outcome. Cell Rep.17(10), 2596–2606 (2016).
   PubMed Web of Science ®Google Scholar
• Stone L . Prostate cancer: on the down-low – low luminal cell CD38 expression is prognostic. Nat. Rev. Urol.14(3), 133 (2017).
   PubMed Web of Science ®Google Scholar
• Zhang M , YangJ, ZhouJet al. Prognostic values of CD38+CD101+PD1+CD8+ T cells in pancreatic cancer. Immunol. Invest.48(5), 466–479 (2019).
   PubMed Web of Science ®Google Scholar
• Jiang Z , WuD, LinS, LiP. CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia. Biomark. Res.4, 23 (2016).
   PubMed Web of Science ®Google Scholar
• Xu L , ChenD, LuC, LiuX, WuG, ZhangY. Advanced lung cancer is associated with decreased expression of perforin, CD95, CD38 by circulating CD3+CD8+ T lymphocytes. Ann. Clin. Lab. Sci.45(5), 528–532 (2015).
   PubMed Web of Science ®Google Scholar
• Lam JH , NgHHM, LimCJet al. Expression of CD38 on macrophages predicts improved prognosis in hepatocellular carcinoma. Front. Immunol.10, 2093 (2019).
   PubMed Web of Science ®Google Scholar
• Yeong J , LimJCT, LeeBet al. High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancer. Front. Immunol.9, 1209–1209 (2018).
   PubMed Web of Science ®Google Scholar
• Perenkov AD , NovikovDV, SakharnovNAet al. [Heterogeneous expression of CD38 gene in tumor tissue in patients with colorectal cancer]. Mol. Biol.46(5), 786–791 (2012).
   Web of Science ®Google Scholar
• Zheng D , LiaoS, ZhuGet al. CD38 is a putative functional marker for side population cells in human nasopharyngeal carcinoma cell lines. Mol. Carcinog.55(3), 300–311 (2016).
   PubMed Web of Science ®Google Scholar
• Ge Y , LongY, XiaoSet al. CD38 affects the biological behavior and energy metabolism of nasopharyngeal carcinoma cells. Int. J. Oncol.54(2), 585–599 (2019).
   PubMed Web of Science ®Google Scholar
• Blacher E , BenBaruch B, LevyAet al. Inhibition of glioma progression by a newly discovered CD38 inhibitor. Int. J. Cancer136(6), 1422–1433 (2015).
   PubMed Web of Science ®Google Scholar
• Chmielewski JP , BowlbySC, WheelerFBet al. CD38 inhibits prostate cancer metabolism and proliferation by reducing cellular NAD(+) pools. Mol. Cancer Res.16(11), 1687–1700 (2018).
   PubMed Web of Science ®Google Scholar
• Liao S , XiaoS, ZhuGet al. CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical cancer. Oncol. Rep.32(6), 2703–2709 (2014).
   PubMed Web of Science ®Google Scholar
• Liao S , XiaoS, ChenHet al. CD38 enhances the proliferation and inhibits the apoptosis of cervical cancer cells by affecting the mitochondria functions. Mol. Carcinog.56(10), 2245–2257 (2017).
   PubMed Web of Science ®Google Scholar
• Li Y , LuZ, CheYet al. Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma. Oncoimmunology6(11), e1356147 (2017).
   PubMed Web of Science ®Google Scholar
• Karimi-Busheri F , ZadorozhnyV, LiT, LinH, ShawlerDL, FakhraiH. Pivotal role of CD38 biomarker in combination with CD24, EpCAM, and ALDH for identification of H460 derived lung cancer stem cells. J. Stem Cells6(1), 9–20 (2011).
   PubMedGoogle Scholar
• Bu X , KatoJ, HongJAet al. CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells. Carcinogenesis39(2), 242–251 (2018).
   PubMed Web of Science ®Google Scholar
• Ehlerding EB , EnglandCG, JiangDet al. CD38 as a PET imaging target in lung cancer. Mol. Pharm.14(7), 2400–2406 (2017).
   PubMedGoogle Scholar
• Cotner T , WilliamsJM, ChristensonL, ShapiroHM, StromTB, StromingerJ. Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content. J. Exp. Med.157(2), 461–472 (1983).
   PubMed Web of Science ®Google Scholar
• Fox R , McMillanR, SpruceW, TaniP, MasonD. Analysis of T lymphocytes after bone marrow transplantation using monoclonal antibodies. Blood60(3), 578–582 (1982).
   PubMed Web of Science ®Google Scholar
• Burel JG , ApteSH, GrovesPL, KleinK, McCarthyJS, DoolanDL. Reduced plasmodium parasite burden associates with CD38+ CD4+ T cells displaying cytolytic potential and impaired IFN-gamma production. PLoS Pathog.12(9), e1005839 (2016).
   PubMed Web of Science ®Google Scholar
• Chatterjee S , DaenthanasanmakA, ChakrabortyPet al. CD38-NAD+axis regulates immunotherapeutic anti-tumor T cell response. Cell Metab.27(1), 85–100.e108 (2018).
   PubMed Web of Science ®Google Scholar
• Bettelli E , CarrierY, GaoWet al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature441(7090), 235–238 (2006).
   PubMed Web of Science ®Google Scholar
• Chen J , ChenYG, ReifsnyderPCet al. Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP-ribosyltransferase 2-dependent fashion. J. Immunol.176(8), 4590–4599 (2006).
   PubMed Web of Science ®Google Scholar
• Hubert S , RissiekB, KlagesKet al. Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2-P2X7 pathway. J. Exp. Med.207(12), 2561–2568 (2010).
   PubMed Web of Science ®Google Scholar
• Feng X , ZhangL, AcharyaCet al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin. Cancer Res.23(15), 4290–4300 (2017).
   PubMed Web of Science ®Google Scholar
• Patton DT , WilsonMD, RowanWC, SoondDR, OkkenhaugK. The PI3K p110delta regulates expression of CD38 on regulatory T cells. PLoS ONE6(3), e17359 (2011).
   PubMed Web of Science ®Google Scholar
• Krejcik J , CasneufT, NijhofISet al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood128(3), 384–394 (2016).
   PubMed Web of Science ®Google Scholar
• Tai YT , AndersonKC. A new era of immune therapy in multiple myeloma. Blood128(3), 318–319 (2016).
   PubMed Web of Science ®Google Scholar
• Tai YT , AndersonKC. Targeting CD38 alleviates tumor-induced immunosuppression. Oncotarget8(68), 112166–112167 (2017).
   PubMedGoogle Scholar
• Romero-Ramirez H , Morales-GuadarramaMT, PelayoR, Lopez-SantiagoR, Santos-ArgumedoL. CD38 expression in early B-cell precursors contributes to extracellular signal-regulated kinase-mediated apoptosis. Immunology144(2), 271–281 (2015).
   PubMed Web of Science ®Google Scholar
• Kumagai M , Coustan-SmithE, MurrayDJet al. Ligation of CD38 suppresses human B lymphopoiesis. J. Exp. Med.181(3), 1101–1110 (1995).
   PubMed Web of Science ®Google Scholar
• Quach TD , HopkinsTJ, HolodickNEet al. Human B-1 and B-2 B cells develop from Lin-CD34+CD38lo stem cells. J. Immunol.197(10), 3950–3958 (2016).
   PubMed Web of Science ®Google Scholar
• Liu XQ , HartDN, MacPhersonGG, GoodMF, WykesMN. Soluble CD38 significantly prolongs the lifespan of memory B-cell responses. Immunology125(1), 14–20 (2008).
   PubMed Web of Science ®Google Scholar
• Hwang HS , SongJH, HyoungBJet al. Clinical impacts of CD38+ B cells on acute cellular rejection with CD20+ B cells in renal allograft. Transplantation89(12), 1489–1495 (2010).
   PubMed Web of Science ®Google Scholar
• Fedele G , FrascaL, PalazzoR, FerreroE, MalavasiF, AusielloCM. CD38 is expressed on human mature monocyte-derived dendritic cells and is functionally involved in CD83 expression and IL-12 induction. Eur. J. Immunol.34(5), 1342–1350 (2004).
   PubMed Web of Science ®Google Scholar
• Frasca L , FedeleG, DeaglioSet al. CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells. Blood107(6), 2392–2399 (2006).
   PubMed Web of Science ®Google Scholar
• Viegas MS , DoCarmo A, SilvaTet al. CD38 plays a role in effective containment of mycobacteria within granulomata and polarization of Th1 immune responses against Mycobacterium avium. Microbes Infect.9(7), 847–854 (2007).
   PubMed Web of Science ®Google Scholar
• Partida-Sanchez S , GasserA, FliegertRet al. Chemotaxis of mouse bone marrow neutrophils and dendritic cells is controlled by adp-ribose, the major product generated by the CD38 enzyme reaction. J. Immunol.179(11), 7827–7839 (2007).
   PubMed Web of Science ®Google Scholar
• Shu B , FengY, GuiYet al. Blockade of CD38 diminishes lipopolysaccharide-induced macrophage classical activation and acute kidney injury involving NF-κB signaling suppression. Cell. Signal.42, 249–258 (2018).
   PubMed Web of Science ®Google Scholar
• Kang J , ParkKH, KimJJ, JoEK, HanMK, KimUH. The role of CD38 in Fcγ receptor (FcγR)-mediated phagocytosis in murine macrophages. J. Biol. Chem.287(18), 14502–14514 (2012).
   PubMed Web of Science ®Google Scholar
• Mallone R , FunaroA, ZubiaurMet al. Signaling through CD38 induces NK cell activation. Int. Immunol.13(4), 397–409 (2001).
   PubMed Web of Science ®Google Scholar
• Sconocchia G , TitusJA, MazzoniAet al. CD38 triggers cytotoxic responses in activated human natural killer cells. Blood94(11), 3864–3871 (1999).
   PubMed Web of Science ®Google Scholar
• Casneuf T , XuXS, AdamsHC3rdet al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv.1(23), 2105–2114 (2017).
   PubMed Web of Science ®Google Scholar
• Deaglio S , ZubiaurM, GregoriniAet al. Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells. Blood99(7), 2490–2498 (2002).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI , Ostrand-RosenbergS, BronteV. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol.12(4), 253–268 (2012).
   PubMed Web of Science ®Google Scholar
• Krejcik J , CasneufT, NijhofISet al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood128(3), 384–394 (2016).
   PubMed Web of Science ®Google Scholar
• Karakasheva TA , WaldronTJ, EruslanovEet al. CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer. Cancer Res.75(19), 4074–4085 (2015).
   PubMed Web of Science ®Google Scholar
• Dilillo DJ , RavetchJV. Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions. Cancer Immunol. Res.3(7), 704–713 (2015).
   PubMed Web of Science ®Google Scholar
• Stevenson FK , BellAJ, CusackRet al. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood77(5), 1071–1079 (1991).
   PubMed Web of Science ®Google Scholar
• Boussi L , NiesvizkyR. Advances in immunotherapy in multiple myeloma. Curr. Opin. Oncol.29(6), 460–466 (2017).
   PubMed Web of Science ®Google Scholar
• De Weers M , TaiYT, VanDer Veer MSet al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol.186(3), 1840–1848 (2011).
   PubMed Web of Science ®Google Scholar
• Overdijk MB , VerploegenS, BogelsMet al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs7(2), 311–321 (2015).
   PubMed Web of Science ®Google Scholar
• Van De Donk NW , MoreauP, PlesnerTet al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood127(6), 681–695 (2016).
   PubMed Web of Science ®Google Scholar
• Laubach JP , RichardsonPG. CD38-targeted immunochemotherapy in refractory multiple myeloma: a new horizon. Clin. Cancer Res.21(12), 2660–2662 (2015).
   PubMed Web of Science ®Google Scholar
• Magarotto V , SalviniM, BonelloF, BringhenS, PalumboA. Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: a new era begins. Leuk. Lymphoma57(3), 537–556 (2016).
   PubMed Web of Science ®Google Scholar
• Raje N , LongoDL. Monoclonal antibodies in multiple myeloma come of age. N. Engl. J. Med.373(13), 1264–1266 (2015).
   PubMed Web of Science ®Google Scholar
• Bride KL , VincentTL, ImSYet al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL). Blood131(9), 995–999 (2018).
   PubMed Web of Science ®Google Scholar
• Verma V , ShrimaliRK, AhmadSet al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat. Immunol.20(9), 1231–1243 (2019).
   PubMed Web of Science ®Google Scholar
• Chen L , DiaoL, YangYet al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov.8(9), 1156–1175 (2018).
   PubMed Web of Science ®Google Scholar
• Malavasi F , FainiAC. Mechanism of action of a new anti-CD38 antibody: enhancing myeloma immunotherapy. Clin. Cancer Res.25(10), 2946–2948 (2019).
   PubMed Web of Science ®Google Scholar